Vanguard Group Inc Eliem Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.57 Trillion
- Q4 2024
A detailed history of Vanguard Group Inc transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,506,257 shares of ELYM stock, worth $6.19 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,506,257
Previous 1,524,868
1.22%
Holding current value
$6.19 Million
Previous $7.76 Million
20.24%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding ELYM
# of Institutions
76Shares Held
51MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$129 Million2.09% of portfolio
-
Janus Henderson Group PLC London, X03.18MShares$13.1 Million0.01% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA2.61MShares$10.7 Million3.29% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.04MShares$4.27 Million0.19% of portfolio
-
Bank Of America Corp Charlotte, NC1.03MShares$4.25 Million0.0% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $109M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...